Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Leases (2019 - 2025)

Historic Current Leases for Iovance Biotherapeutics (IOVA) over the last 4 years, with Q3 2025 value amounting to $6.3 million.

  • Iovance Biotherapeutics' Current Leases changed N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2024, which is 6582.23% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Current Leases stood at $6.3 million for Q3 2025.
  • Iovance Biotherapeutics' Current Leases' 5-year high stood at $12.9 million during Q4 2024, with a 5-year trough of $6.3 million in Q3 2025.
  • Moreover, its 3-year median value for Current Leases was $10.5 million (2023), whereas its average is $9.7 million.
  • In the last 5 years, Iovance Biotherapeutics' Current Leases skyrocketed by 6582.23% in 2024 and then tumbled by 2328.04% in 2025.
  • Iovance Biotherapeutics' Current Leases (Quarter) stood at $7.8 million in 2023, then skyrocketed by 65.82% to $12.9 million in 2024, then plummeted by 51.29% to $6.3 million in 2025.
  • Its Current Leases was $6.3 million in Q3 2025, compared to $7.1 million in Q2 2025 and $8.5 million in Q1 2025.